Related Experiment Video
Updated: May 25, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
PDCD1 polymorphisms are not associated with Takayasu's arteritis in Turkey
Haner Direskeneli1, Ezgi Tuna-Erdoğan, Feyza Gündüz
1Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey. hanerdireskeneli@gmail.com
Insights
Genetic variations in the PDCD1 gene, specifically PD-1.3, PD-1.5, and PD-1.6 polymorphisms, were investigated for their role in Takayasu
Area of Science:
- Immunogenetics
- Rheumatology
- Vascular Biology
Background:
- Takayasu's arteritis (TA) is a rare, chronic inflammatory condition affecting large arteries, primarily the aorta and its branches.
- The etiology of TA remains largely unknown, but associations with autoimmune diseases suggest a genetic component.
- Programmed death-1 (PD-1) protein, encoded by the PDCD1 gene, plays a crucial role in immune regulation and has been linked to various autoimmune disorders and vasculitides.
Purpose of the Study:
- To investigate the potential association between single nucleotide polymorphisms (SNPs) in the PDCD1 gene and susceptibility to Takayasu's arteritis (TA).
- To analyze PD-1.3, PD-1.5, and PD-1.6 polymorphisms within the PDCD1 gene in a Turkish population with TA.
Main Methods:
- A case-control study involving 229 TA patients meeting the 1990 ACR classification criteria and 193 healthy controls (HC).
- Genotyping of PDCD1 gene polymorphisms (PD-1.3, PD-1.5, PD-1.6) was performed using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) analysis.
Main Results:
- No significant difference in the distribution of the PD-1.5 TT genotype was observed between TA patients and healthy controls (13.3% vs. 11.4%).
- PD-1.3 and PD-1.6 polymorphisms showed limited variability and did not differ between the study groups.
- Rare genotypes, such as PD-1.3 AA (1.4% vs. 1.0%) and PD-1.6 AG (22.4% vs. 19.2%), were similarly present in both TA patients and controls.
Conclusions:
- The studied PDCD1 gene polymorphisms (PD-1.3, PD-1.5, PD-1.6) are not associated with susceptibility to Takayasu's arteritis in the investigated Turkish population.
- These findings suggest that variations in these specific PDCD1 gene loci do not confer a predisposition to TA, despite their known links to other autoimmune conditions.
Objectives:
Takayasu's arteritis (TA) is a chronic arterial inflammation of unknown etiology involving mainly the aorta and its major branches. Based on the associations of programmed death-1 (PD-1) protein encoding gene (PDCD1) with connective tissue diseases and vasculitides, PDCD1 polymorphisms are studied for susceptibility to TA in this study.
Methods:
The study group is made up of TA patients (n=229) fulfilling the 1990 ACR classification criteria and compared to 193 healthy controls (HC). PD-1.3, PD-1.5 and PD-1.6 single nucleotide polymorphisms of PDCD1 gene are genotyped by polymerase chain reaction and restriction analysis (PCR-RFLP).
Results:
The distribution of PD-1.5 polymorphism in TA patients and HC revealed a similar presence of TT genotype in patients and controls (13.3% vs. 11.4%). PD-1.3 and PD-1.6 were less polymorphic and did not differ between the groups. Rare AA genotype of PD-1.3 (1.4% vs. 1.0%) and AG genotype of PD-1.6 was again similarly (22.4% vs. 19.2%) present in TA and HC.
Conclusions:
PD-1.3, 1.5 and 1.6 polymorphisms of PDCD1 gene, which were shown to be associated with various autoimmune disorders and vasculitides, are not associated with a susceptibility to TA in Turkish population.
More Related Videos
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenomics: Identification of New Drug Targets